Identifying compelling investment opportunities in healthcare

In episode two of our fortnightly COVID-19 webinar series, healthcare sector head, Dr Nick Cameron explains how the Antipodes team examines companies within the global healthcare space.

This webinar was recorded on 9 April, 2020. To view the full webinar, including comprehensive insights into Antipodes’ portfolio, click here.

You can register for upcoming webinars in the series here.


Episode 2 Part 2 – Transcript:

Dr Nick Cameron:

Some key points for investors out there on how we think about investing in the space:

  • Typically what we look for are companies that innovate, not fast followers, that are ones that provide very innovative or novel products and services. This can provide a wider moat against competition and also command greater pricing power in markets which are typically seeing very significant pressure on pricing. We’re quite unique in healthcare, in particular biotech and pharma, where patents also provide very strong protection around product revenues and some resilience longer term.
  • We like companies with diversified earnings streams and that also can provide a greater margin of safety, rather than having all your eggs in one basket. It also can provide lower earnings volatility in cyclically exposed businesses and healthcare, but also, more importantly, I think in this stage of the evolution of the healthcare market – having multiple avenues or options to unlock value through other businesses within your broader business also provides optionality and potential to unlock shareholder value.
  • Products and services that are less discretionary in nature is also something we look for and have generally a lower chance of being deferred or being curtailed during times of difficulty.
  • Finally, we try to avoid exposures to companies or businesses that have a disproportionate exposure to government revenues and payers. Overall we think these businesses are more at risk of having funding cuts, particularly when healthcare budgets are burgeoning with the aging population and growing utilisation.

Key examples that we have in the portfolio include Merck & Co. It has a number of these factors going for them. Oncology is a very defensive and non-discretionary part of medicine. It’s vaccines business is very defensible and stable through economic cycles and also is the animal health business. Roche Holding AG, as well, is probably the premier innovator in the pharmaceutical space. It’s well diversified and margins are improving.

And then finally, I’ll probably just note, just how wide the variety of opportunities we have in healthcare is. The valuation or multiple divergence between the various subsectors is quite wide. And you can see there (refer to slide 5) that pharmaceuticals, in particular, have been languishing over quite some period and it’s no surprise that that’s where we’re finding a lot of opportunities at present.

View the full webinar

This communication was prepared by Antipodes Partners Limited (ABN 29 602 042 035, AFSL 481 580) (Antipodes). Antipodes believes the information contained in this communication is based on reliable information, no warranty is given as to its accuracy and persons relying on this information do so at their own risk. This communication is for general information only and was prepared for multiple distribution and does not take account of the specific investment objectives of individual recipients and it may not be appropriate in all circumstances. Persons relying on this information should do so in light of their specific investment objectives and financial situations. Any person considering action on the basis of this communication must seek individual advice relevant to their particular circumstances and investment objectives. Subject to any liability which cannot be excluded under the relevant laws, Antipodes disclaim all liability to any person relying on the information contained on this website in respect of any loss or damage (including consequential loss or damage), however caused, which may be suffered or arise directly or indirectly in respect of such information.
Any opinions or forecasts reflect the judgment and assumptions of Antipodes on the basis of information at the date of publication and may later change without notice. Any projections are estimates only and may not be realised in the future. Information on this website is not intended as a securities recommendation or statement of opinion intended to influence a person or persons in making a decision in relation to investment. Unauthorised use, copying, distribution, replication, posting, transmitting, publication, display, or reproduction in whole or in part of the information contained on the website is prohibited without obtaining prior written permission from Antipodes.
Pinnacle Fund Services Limited ABN 29 082 494 362 AFSL 238371 is the product issuer of funds managed by Antipodes.  Any potential investor should consider the relevant Product Disclosure Statement available at when deciding whether to acquire, or continue to hold units in a fund. The issuer is not licensed to provide financial product advice.  Please consult your financial adviser before making a decision. Past performance is not a reliable indicator of future performance.
14 April 2020